MENTAX-TC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MENTAX-TC (MENTAX-TC).
MENTAX-TC (butenafine hydrochloride) is a benzylamine antifungal agent that inhibits the synthesis of ergosterol, a critical component of fungal cell membranes, by inhibiting the enzyme squalene epoxidase. This leads to accumulation of squalene and disruption of membrane integrity, resulting in fungal cell death.
| Metabolism | Butenafine is primarily metabolized via oxidation and N-dealkylation pathways, involving cytochrome P450 enzymes, though specific isoforms have not been fully characterized. Following topical application, systemic absorption is minimal (<5%), and absorbed drug undergoes hepatic metabolism. |
| Excretion | Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine, ~60% in feces as metabolites, <1% in bile as unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 20 hours (range 16-24 hours), allowing once-daily dosing. |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is approximately 2.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical bioavailability is negligible (<5%) due to minimal percutaneous absorption; systemic exposure after topical application is very low. |
| Onset of Action | Topical: Clinical improvement noted within 2-3 days of twice-daily application. |
| Duration of Action | After topical application, therapeutic effect persists for 24 hours, supporting once-daily dosing regimen. |
Apply a thin layer to affected area once daily for 2-4 weeks.
| Dosage form | CREAM |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | Children ≥12 years: Same as adult. Children <12 years: Not recommended. |
| Geriatric use | Same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MENTAX-TC (MENTAX-TC).
| Breastfeeding | No human data on excretion in breast milk. M/P ratio unknown. Caution advised; use only if clearly needed. |
| Teratogenic Risk | Insufficient human data; animal studies not available. Risk cannot be excluded. Avoid in first trimester unless benefit outweighs risk. |
| Fetal Monitoring | Monitor for local adverse effects; no specific fetal monitoring required. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to butenafine hydrochloride or any component of the formulation"]
| Precautions | ["For external use only; not for ophthalmic, oral, or intravaginal use","Avoid contact with eyes and mucous membranes","Discontinue if irritation or sensitization occurs","Use caution in patients with known hypersensitivity to allylamine antifungal agents"] |
Loading safety data…
| Fertility Effects | No known effects on fertility. |